Previous studies showed no impact of PNPLA3 high risk alleles on treatment outcome in unselected CHC patients [23], but in a selected subgroup of HCV GT 1/4-patients with advanced fibrosis [52]. This evidence concerns the gene PNPLA3 and cryohydrocytosis.